Richard A. Rudick

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation

Affiliated withCleveland Clinic Foundation

Research Area

Biography

Richard A. Rudick has not added Biography.
If you are Richard A. Rudick and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 106	2014

Other Publications

Article	Year
Sex differences in cytokine responses to myelin peptides in multiple sclerosis. Journal of neuroimmunology\| PubMed ID: 12225904	2002
Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 12617260	2003
Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes. Methods (San Diego, Calif.)\| PubMed ID: 12725798	2003
Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals. Journal of neurovirology\| PubMed ID: 12775413	2003
Interferons in relapsing remitting multiple sclerosis. Lancet\| PubMed ID: 12781561	2003
Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression. Journal of neuroimmunology\| PubMed ID: 12965264	2003
Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells. Journal of neuroimmunology\| PubMed ID: 12965266	2003
Biologic impact of interferon antibodies, and complexities in assessing their clinical significance. Neurology\| PubMed ID: 14610110	2003
Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis. Archives of neurology\| PubMed ID: 14676048	2003
Multiple sclerosis: disease markers accelerate progress. Lancet neurology\| PubMed ID: 14693099	2004
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. Journal of neuroimaging : official journal of the American Society of Neuroimaging\| PubMed ID: 15228760	2004
Defining interferon beta response status in multiple sclerosis patients. Annals of neurology\| PubMed ID: 15389896	2004
Association of fatigue and brain atrophy in multiple sclerosis. Journal of the neurological sciences\| PubMed ID: 15694198	2005
Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 15794385	2005
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert review of neurotherapeutics\| PubMed ID: 15853576	2004
Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 16042223	2005
Effects of sex hormones on costimulatory molecule expression in multiple sclerosis. Journal of neuroimmunology\| PubMed ID: 16046001	2005
Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation. Annals of neurology\| PubMed ID: 16130097	2005
Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Archives of neurology\| PubMed ID: 16157744	2005
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. The New England journal of medicine\| PubMed ID: 16510745	2006
Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Annals of neurology\| PubMed ID: 16786526	2006
Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-beta1a? Nature clinical practice. Neurology\| PubMed ID: 16932486	2005
Drug Insight: interferon treatment in multiple sclerosis. Nature clinical practice. Neurology\| PubMed ID: 16932519	2006
Chemokine receptors as biomarkers in multiple sclerosis. Disease markers\| PubMed ID: 17124344	2006
Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Annals of neurology\| PubMed ID: 17427920	2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet neurology\| PubMed ID: 17434098	2007
Interferon-beta for multiple sclerosis: Long-term benefits? Annals of neurology\| PubMed ID: 17444503	2007
Developing a mentorship program for clinical researchers. The Journal of continuing education in the health professions\| PubMed ID: 17576629	2007
Health-related quality of life in multiple sclerosis: effects of natalizumab. Annals of neurology\| PubMed ID: 17696126	2007
Novel interferon-beta-induced gene expression in peripheral blood cells. Journal of leukocyte biology\| PubMed ID: 17709400	2007
Interferon-beta treatment for multiple sclerosis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics\| PubMed ID: 17920544	2007
Biomarkers for interferon response in MS: are we there yet? Neurology\| PubMed ID: 18362268	2008
Gray matter atrophy in multiple sclerosis: a longitudinal study. Annals of neurology\| PubMed ID: 18661561	2008
LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert opinion on biological therapy\| PubMed ID: 18774923	2008
Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment. CNS drugs\| PubMed ID: 18788835	2008
Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. Journal of the neurological sciences\| PubMed ID: 19100997	2009
Brain atrophy as an outcome measure for multiple sclerosis clinical trials: a "no-brainer"? Neurology\| PubMed ID: 19221291	2009
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of neurology\| PubMed ID: 19308305	2009
Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet neurology\| PubMed ID: 19446274	2009
Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association\| PubMed ID: 19595872	2006
Natalizumab for the treatment of relapsing multiple sclerosis. Biologics : targets & therapy\| PubMed ID: 19707353	2008
Gray-matter injury in multiple sclerosis. The New England journal of medicine\| PubMed ID: 19812410	2009
Do interferon beta-1b and glatiramer acetate grow brain? Lancet neurology\| PubMed ID: 19909906	2009
Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta. Annals of the New York Academy of Sciences\| PubMed ID: 20074275	2009
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the neurological sciences\| PubMed ID: 20236661	2010
A radical proposal: integrate clinical investigation into the U.S. health care system. Science translational medicine\| PubMed ID: 20368168	2009
Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology\| PubMed ID: 20421570	2010
The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology\| PubMed ID: 20421572	2010
Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology\| PubMed ID: 20551692	2010
Measuring disability in relapsing-remitting MS. Neurology\| PubMed ID: 20592252	2010
Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Archives of neurology\| PubMed ID: 20625068	2010
Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Annals of neurology\| PubMed ID: 20737514	2010
Multiple sclerosis: is multiple sclerosis caused by venous insufficiency? Nature reviews. Neurology\| PubMed ID: 20811464	2010
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Therapeutic advances in neurological disorders\| PubMed ID: 21179614	2010
Web-based self-management for patients with multiple sclerosis: a practical, randomized trial. Telemedicine journal and e-health : the official journal of the American Telemedicine Association\| PubMed ID: 21214498	2011
Diagnostic criteria in multiple sclerosis: headed in the right direction but still a ways to go. Annals of neurology\| PubMed ID: 21387367	2011
Beta-interferon for multiple sclerosis. Experimental cell research\| PubMed ID: 21396360	2011
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs. Current opinion in neurology\| PubMed ID: 21455068	2011
Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. PloS one\| PubMed ID: 21602934	2011
Oral treatment for multiple sclerosis. Lancet neurology\| PubMed ID: 22014437	2011
The role of cell type-specific responses in IFN-β therapy of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 22106296	2011
Multiple sclerosis, natalizumab, and PML: helping patients decide. Cleveland Clinic journal of medicine\| PubMed ID: 22123928	2011
Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology\| PubMed ID: 22282644	2012
MS clinical trials: what can subgroup analyses teach us? Lancet neurology\| PubMed ID: 22494954	2012
The elusive biomarker for personalized medicine in multiple sclerosis: the search continues. Neurology\| PubMed ID: 22573625	2012
Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis. Neurology\| PubMed ID: 22581931	2012
Early tolerability and safety of fingolimod in clinical practice. Journal of the neurological sciences\| PubMed ID: 23040960	2012
Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet neurology\| PubMed ID: 23153407	2012
Time to integrate clinical and research informatics. Science translational medicine\| PubMed ID: 23197569	2012
Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Annals of neurology\| PubMed ID: 23378325	2013
Author response. Neurology\| PubMed ID: 23544194	2013
Author response to comment on "time to integrate clinical and research informatics". Science translational medicine\| PubMed ID: 23552368	2013
Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic. JAMA neurology\| PubMed ID: 23599930	2013
MRI lesions: a surrogate for relapses in multiple sclerosis? Lancet neurology\| PubMed ID: 23743083	2013
Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 23818018	2013
Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 24057430	2014
Assessing treatment response to interferon-β: is there a role for MRI? Neurology\| PubMed ID: 24336144	2014
Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology\| PubMed ID: 24871874	2014
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology\| PubMed ID: 24898925	2014